|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Bondronat inj conc[骨得寧 濃縮注射劑] information |
|
|
|
製造商 |
Roche |
|
代理/經銷商 |
Roche |
|
成份 |
Ibandronic acid |
|
適應症 |
Prevention of skeletal events( pathological fracture, bone complications requiring radiotherapy or surgery) in patients with breast cancer & bone metastases. Treatment of pathologically elevated serum Ca levels as a result of tumours. |
|
用量 |
Treatment of metastatic bone disease 6 mg as a 1-hr IV infusion every 3-4 weeks. Treatment of hypercalcemia Single IV infusion of 2-4 mg, dependent on patient's pre-treatment serum Ca level. |
|
過量 |
View Bondronat[骨得寧] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Pregnancy & lactation; children. |
|
注意事項 |
Monitor renal function, serum Ca, phosphate & Mg levels; severe hepatic impairment. |
|
不良反應 |
Rise in body temp, flu-like syndrome, GI disturbances, bronchoconstriction (in aspirin-sensitive asthmatic patients), headache, myalgia, asthenia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
[Click for Bondronat[骨得寧] detailed prescribing infomation]
View more drug interactions with Bondronat[骨得寧] |
|
儲存 |
View Bondronat[骨得寧] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Bondronat[骨得寧] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Bondronat[骨得寧] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Bondronat 濃縮注射劑 |
|
Bondronat 2 mg/2 mL x 5's |
|
Bondronat 6 mg/6 mL x 5's |
|
|
|
Manufacturer: |
Roche |
|
Distributor: |
Roche
|
|
|
|
